News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Illumina, Inc. (ILMN) Patent Claim May be Reconsidered


11/26/2012 9:07:35 AM

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NAS: ILMN) announced that Magistrate Judge Elizabeth D. Laporte of the U.S. District Court for the Northern District of California granted Illumina's request to file a motion seeking reconsideration of the Court's October 16, 2012 ruling invalidating certain claims of U.S. Patent No. 6,306,597, which is being asserted by Illumina against Complete Genomics, Inc. Under Judge Laporte's order, Illumina is permitted to file briefing asking the Court to reconsider its earlier ruling invalidating claims 14 and 15 of the '597 patent. Illumina will seek a January 8, 2013 hearing date on the motion for reconsideration.

Jay Flatley, Illumina's President and CEO, stated, "We are very pleased that the Court has agreed to review its earlier decision invalidating certain claims of Illumina's '597 patent. We continue to believe that this patent covers important and novel inventions that Complete Genomics has misappropriated."

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Illumina, Inc.

Investors:

Rebecca Chambers

Investor Relations

858-255-5243

rchambers@illumina.com

or

Media:

Jennifer Temple

Public Relations

858-882-6822

pr@illumina.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES